GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bakhu Holdings Corp (OTCPK:BKUH) » Definitions » Sloan Ratio %

Bakhu Holdings (Bakhu Holdings) Sloan Ratio % : 0.00% (As of Jan. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Bakhu Holdings Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Bakhu Holdings's Sloan Ratio for the quarter that ended in Jan. 2024 was 0.00%.

Warning Sign:

When sloan ratio (-2100.64)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.

As of Jan. 2024, Bakhu Holdings has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Bakhu Holdings Sloan Ratio % Historical Data

The historical data trend for Bakhu Holdings's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bakhu Holdings Sloan Ratio % Chart

Bakhu Holdings Annual Data
Trend Jul08 Jul09 Jul10 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -2,100.64

Bakhu Holdings Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Bakhu Holdings's Sloan Ratio %

For the Drug Manufacturers - Specialty & Generic subindustry, Bakhu Holdings's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bakhu Holdings's Sloan Ratio % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bakhu Holdings's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Bakhu Holdings's Sloan Ratio % falls into.



Bakhu Holdings Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Bakhu Holdings's Sloan Ratio for the fiscal year that ended in Jul. 2023 is calculated as

Sloan Ratio=(Net Income (A: Jul. 2023 )-Cash Flow from Operations (A: Jul. 2023 )
-Cash Flow from Investing (A: Jul. 2023 ))/Total Assets (A: Jul. 2023 )
=(-10.305--0.432
-0.021)/0.471
=-2,100.64%

Bakhu Holdings's Sloan Ratio for the quarter that ended in Jan. 2024 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Jan. 2024 )
=(-1.922--0.724
-0)/0.827
=-144.86%

Bakhu Holdings's Net Income for the trailing twelve months (TTM) ended in Jan. 2024 was -3.505 (Apr. 2023 ) + 2.835 (Jul. 2023 ) + -1.131 (Oct. 2023 ) + -0.121 (Jan. 2024 ) = $-1.92 Mil.
Bakhu Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jan. 2024 was -0.054 (Apr. 2023 ) + -0.054 (Jul. 2023 ) + -0.389 (Oct. 2023 ) + -0.227 (Jan. 2024 ) = $-0.72 Mil.
Bakhu Holdings's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jan. 2024 was 0 (Apr. 2023 ) + 0 (Jul. 2023 ) + 0 (Oct. 2023 ) + 0 (Jan. 2024 ) = $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bakhu Holdings  (OTCPK:BKUH) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Jan. 2024, Bakhu Holdings has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Bakhu Holdings Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Bakhu Holdings's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Bakhu Holdings (Bakhu Holdings) Business Description

Traded in Other Exchanges
N/A
Address
One World Trade Center, Suite 130, Long Beach, CA, USA, 90831
Bakhu Holdings Corp is a development stage company engaged in the production, manufacturing, and sale of cannabis and byproducts. The company also provides cannabis-related research, teaching and education for both medical and other purposes, and all medical uses and applications of cannabis, within the Territory.
Executives
Tom Vaknin director SPYROU KYPRIANOU 16, PYGROS / LIMMASOL G4 4529
Moshe Morgenstern director MENACHEM BEGIN 88, PETAH TIKVAH/CENTRAL DISTRICT L3 49504
Geoffrey Robert Dixon 10 percent owner 16 SHOBY LANE, GRIMSTON X0 LE14 3DD
Michael Richard Hawthorne officer: Deputy CEO 20 LARKSBOROUGH AVENUE, COUNTY DOWN X0 BT23 8SU
Garcia La Sienra Garcia Juan Carlos director, officer: CFO 3 SHANEWOOD CT, THE WOODLANDS TX 77382
Sagi Rami Rozen director HOUSE NUMBER 8, 8 AGIAS TRIADAS STREET (MOUTTAGIAKA), LIMASSOL G4 4527
Cell Science Holding, Ltd. 10 percent owner PANTELI KATELARI 18A, AGIOS IOANNIS, LIMASSOL G4 3012
Mentone, Ltd. 10 percent owner 3 COPLOW CRESCENT, SYSTON, LEICESTER X0 LE7 2JE
Inter-m Traders Fz, Lle 10 percent owner 18A PENTELI KATELARI, LIMASSOL G4 3021
Thomas K Emmitt director, officer: President, CEO and Secretary ONE WORLD TRADE CENTER, SUITE 130, LONG BEACH CA 90831
Aristotle Popolizio director 206 PASSAIC AVENUE, ROSELAND NJ 07068
Evripides Drakos director 139C GLOUCESTER TERRACE, LANCASTER GATE, LONDON X0 W2 6DX
Peter Whitton director 3 COPLOW CRESCENT, SYSTON LEICESTER X0 LE7 2JE
Oz Corp 10 percent owner 24328 VERMONT AVENUE, SUITE 300, HARBOR CITY CA 90710